晚期非小细胞肺癌肿瘤组织与配对循环肿瘤DNA中EGFR突变状态不一致性的综合分析
本研究纳入2463例具有配对肿瘤组织与循环肿瘤DNA(ctDNA)标本的患者,用ARMS法检测EGFR突变,对1017例携带突变者中472例接受EGFR酪氨酸激酶抑制剂治疗者的三个不一致组进行分析。结果显示三组中位无进展生存期相似(p=0.062),ddPCR和二代测序复核发现组B中27例实际携带EGFR突变、组C中64例ctDNA复核阳性。结论认为瘤内异质性和ARMS法灵敏度相对较低导致不一致,ctDNA→组织补充模式可能是合理的临床检测流程。
要点
- 2463例配对标本中1017例经ARMS检出EGFR突变,其中472例接受EGFR TKI治疗。
- 三组接受EGFR TKI患者的中位无进展生存期相似(p=0.062)。
- ddPCR和二代测序复核发现组B中27例、组C中64例实际携带EGFR突变。
核心结论
- 瘤内异质性和ARMS法相对较低的灵敏度是肿瘤组织与ctDNA之间EGFR突变状态不一致的原因。
- ctDNA→TT模式可能是确定EGFR突变状态的合理临床流程。
研究设计与样本
- 研究纳入2463例具有配对肿瘤组织和ctDNA标本、经ARMS法检测EGFR突变状态并接受EGFR TKI治疗的患者,分为三组:A组肿瘤组织阳性/ctDNA阳性,B组肿瘤组织阴性/ctDNA阳性,C组肿瘤组织阳性/ctDNA阴性。
- 对EGFR突变状态不一致的患者采用微滴数字PCR(ddPCR)和二代测序复核,同时对手术肿瘤标本进行显微切割后以ddPCR检测EGFR突变。
主要发现
- 2463例配对标本中1017例经ARMS在肿瘤组织和/或ctDNA中检出EGFR突变,其中472例接受EGFR TKI治疗,A、B、C组分别为264例、28例、180例。
- 三组接受EGFR TKI患者的中位无进展生存期相似(p=0.062)。
- 对活检标本(n=22)和显微切割手术标本(n=5)行ddPCR和二代测序,发现B组中27例携带EGFR突变。
- 经ddPCR复核,C组中64例患者ctDNA检测EGFR突变阳性。
- ctDNA→TT模式与TT→ctDNA模式检测效率相似,且节省约30%的肿瘤组织。
临床怎么用
- 作者认为ctDNA→TT模式可能是确定EGFR突变状态的合理临床流程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to address the underlying reasons for and clinical significance of the discordant EGFR mutation (EGFRm) status between tumor tissue (TT) and circulating tumor DNA (ctDNA). METHODS: Three groups of EGFR tyrosine kinase inhibitor (EGFR TKI)-treated patients whose EGFRm status was determined by the amplification refractory mutation system (ARMS) were included (group A, TT-positive/ctDNA-positive EGFRm status; group B, TT-negative/ctDNA-positive EGFRm status; and group C, TT-positive/ctDNA-negative EGFRm status). Patients with discordant EGFRm status were reevaluated by droplet digital polymerase chain reaction (ddPCR) and next-generation sequencing. Meanwhile, surgical tumor specimens were microdissected for EGFRm detection by ddPCR. RESULTS: Of the 2463 patients with matched TT and ctDNA specimens, 1017 patients carried EGFRm in TT and/or ctDNA by the ARMS. Of these 1017 patients, 472 received EGFR TKIs, including 264, 28, and 180 in groups A, B, and C, respectively. The median progression-free survivals of those receiving EGFR TKIs across the three groups were similar (p = 0.062). Through ddPCR and next-generation sequencing of biopsy specimens (n = 22) and microdissected surgical specimens (n = 5), 27 patients in group B were identified as harboring EGFRm. After reevaluation by ddPCR, 64 patients in group C tested positive for EGFRm in their ctDNA. ctDNA as a screen for EGFRm then tissues as supplement (ctDNA→TT pattern) had similar detection efficiency and saved about 30% of TT compared with TT for initial EGFRm detection followed by ctDNA (TT→ctDNA pattern). CONCLUSIONS: Intratumor heterogeneity and the relatively low sensitivity of the ARMS contributed to discordant EGFRm status between TT specimens and ctDNA. The ctDNA→TT pattern might be a rational clinical procedure for EGFRm determination.
引用
- Wan R, Wang Z, Lee JJ, et al. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28552765. doi:10.1016/j.jtho.2017.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。